- October 6, 2020
12:30 PM - 5:00 PM ET
SAVE THE DATE!
Registration is free and will be open in August 2020.
Meeting materials and registration information will be posted closer to the event date.
This meeting will be hosted virtually.
ABOUT THIS EVENT
On October 6, 2020, FDA will be hosting a virtual public meeting on Patient-Focused Drug Development for Stimulant Use Disorder. This meeting will provide FDA the opportunity to obtain input from individuals who are struggling or have struggled with the use of cocaine, crystal meth, methamphetamine, or misuse of prescription stimulants such as Adderall or Ritalin. Family members, advocates, caregivers and other stakeholders are encouraged to participate and share their views on the condition. In particular, FDA is interested in hearing perspectives on the:
- Health effects and daily impacts of their condition
- Impact (if any) of opioid and polysubstance use on their condition
- Treatment goals
- Decision factors considered when seeking out or selecting a treatment
If you are an individual with stimulant use disorder or a family member/caregiver of an individual with stimulant use disorder and are interested in being a panelist at the meeting to discuss your experience with the condition, please contact PatientFocused@fda.hhs.gov by September 21st, 2020.
Questions about this public meeting can be emailed to the CDER Patient-Focused Drug Development Staff at PatientFocused@fda.hhs.gov.